A. Lloyd

发表

Review of utility values for economic modeling in type 2 diabetes.

P. McEwan, A. Beaudet, J. Clegg, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Excess Morbidity and Cost of Failure to Achieve Targets for Blood Pressure Control in Europe

L. Hansson, Z. Kopp, A. Lloyd, 2002, Blood pressure.

Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists

I. Pavord, E. Bateman, D. Esser, 2016, Applied Health Economics and Health Policy.

Cost-Effectiveness Comparison of Tizanidine and Baclofen in the Management of Spasticity

A. Lloyd, P. Anderson, D. Rushton, 2012, PharmacoEconomics.

The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine.

P. Conway, A. Lloyd, E. McIntosh, 2003, Vaccine.

Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.

D. Price, A. Gray, R. Gale, 2011, Respiratory medicine.

Comment on: “Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists”

I. Pavord, E. Bateman, D. Esser, 2015, Applied Health Economics and Health Policy.

PDB18 Direct Medical Costs of Diabetes Mellitus in China: Annual Cost of Illness and Long-Term Projections Using a Validated Diabetes Model

V. Foos, P. McEwan, A. Lloyd, 2012 .

A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial

A. Lloyd, T. Evers, A. Holman, 2008 .

Long-term validation of the CORE diabetes model in Type 1 and Type 2 diabetes

V. Foos, P. McEwan, A. Lloyd, 2012 .

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects

M. Rose, D. Scott, A. Lloyd, 2008, The European Journal of Health Economics.

Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma.

J. Plumb, A. Lloyd, J. Hutchinson, 2002, Respiratory medicine.

The current and future burden and cost of overactive bladder in five European countries.

C. Kelleher, P. Reeves, D. Irwin, 2006, European urology.

Interventions after artificial insemination: conception rates, pregnancy survival, and ovarian responses to gonadotropin-releasing hormone, human chorionic gonadotropin, and progesterone.

J. Stevenson, A. Lloyd, D. Eborn, 2007, Journal of dairy science.

P32. Economic evaluation of the use of tinzaparin (Innohep??) in the treatment of deep vein thrombosis

A. Lloyd, U. Hoffmeyer, F. Valette, 1996 .

A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany

A. Lloyd, C. Roeder, E. Falla, 2019, International journal of women's health.

Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK

K. Boye, L. Timlin, A. Beaudet, 2011, Journal of medical economics.

Financial and Health Costs of Uncontrolled Blood Pressure in the United Kingdom

A. Lloyd, C. Schmieder, N. Marchant, 2012, PharmacoEconomics.

Major bleeding rates after prophylaxis against venous thromboembolism: Systematic review, meta-analysis, and cost implications

M. Egger, D. Scott, A. Lloyd, 2004, International Journal of Technology Assessment in Health Care.

An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy

P. Reeves, J. Cooke, A. Lloyd, 2004, Pharmacy World and Science.

Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.

A. Briggs, S. Sullivan, M. Hoogendoorn, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States

J. Best, M. Deyoung, J. Gaebler, 2012, Journal of medical economics.

Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin.

A. Lloyd, W. Sawyer, P. Hopkinson, 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Validation of the IMS CORE Diabetes Model.

V. Foos, P. McEwan, A. Lloyd, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients

A. Lloyd, P. Anderson, A. Bearne, 2004, Pharmacy World and Science.

Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective

E. Choy, G. Zlateva, A. Sadosky, 2010, Current medical research and opinion.

The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective

E. Choy, G. Zlateva, A. Lloyd, 2012, Journal of medical economics.

Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting.

Ping Zhang, Andrew Briggs, Jacob Barhak, 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US

J. Best, S. Brunell, Y. Samyshkin, 2012, Journal of medical economics.

PRM58 Long-Term Validation of the IMS CORE Diabetes Model in Type 1 and Type 2 Diabetes

V. Foos, P. McEwan, A. Lloyd, 2012 .

Estimating the impact of different methods of utility assessment on the value of interventions in Type 2 diabetes

W. Herman, V. Foos, A. Lloyd, 2011 .

Economic evaluation of extended and conventional prophylaxis with enoxaparin against venous thromboembolism in patients undergoing surgery for abdominal cancer

D. Gozzard, A. Lloyd, A. Hutchings, 2004 .

Costs and outcomes associated with IVF using recombinant FSH.

W. Ledger, A. Lloyd, P. Anderson, 2009, Reproductive biomedicine online.

A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.

A. Lloyd, T. Evers, A. Holman, 2008, Current Medical Research and Opinion.

Economic Evaluation of the Use of Nadroparin in the Treatment of Deep-Vein Thrombosis in Switzerland

A. Lloyd, U. Hoffmeyer, Elizabeth C. Wakerly, 1997, The Annals of pharmacotherapy.

Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective

E. Choy, G. Zlateva, A. Sadosky, 2010, Current medical research and opinion.

Cost-effectiveness of low-level heat wrap therapy for low back pain.

R. Akehurst, D. Scott, A. Lloyd, 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting.

A. Briggs, A. Gray, J. Barhak, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.